Dual-energy CT-based assessment of the trabecular bone in vertebrae.

BACKGROUND: Osteoporosis can cause severe fractures of bone structures. One important indicator for pathology is a lowered bone mineral density (BMD) - conventionally assessed by dual-energy X-ray absorptiometry (DXA). Dual-energy CT (DECT) - being an alternative that is increasingly used in the clinics - allows the computation of the spatial BMD distribution. OBJECTIVES: Using DECT, the trabecular bone of vertebrae is examined. Several analysis methods for revealing the bone density distribution as well as appropriate visualization methods for detecting regions of lowered BMD are needed for computer-assisted diagnosis (CAD) of osteoporosis. The hypothesis that DECT is better suited than DXA for the computation of local BMD is investigated. METHODS: Building on a model of the interaction of X-rays with bone tissue, novel methods for assessing the spatial structure of the trabecular bone are presented. CAD of DECT image data is facilitated by segmenting the regions of interest interactively and with an Active Shape Model, respectively. The barycentric space of fractional volumes is introduced as a novel means for analyzing bone constitution. For 29 cadaver specimens, DECT as well as DXA has been examined. BMD values derived from both modalities are compared to local force measurements. In addition, clinical data from two patients who underwent DECT scanning for a different reason is analyzed retrospectively. RESULTS: A novel automated delineation method for vertebrae has been successfully applied to DECT data sets. It is shown that localized BMD measurements based on DECT show a stronger linear correlation (R² = 0.8242, linear regression) to local force measurements than density values derived from DXA (R² = 0.4815). CONCLUSIONS: DECT based BMD assessment is a method to extend the usage of increasingly acquired DECT image data. The developed DECT based analysis methods in conjunction with the visualization provide more detailed information for both, the radiologist and the orthopedist, compared to standard DXA based analysis.

'In silico' oncology for clinical decision making in the context of nephroblastoma.

The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials) -- an Integrated Project, partly funded by the EC (FP6-2005-IST-026996)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients. Cancer treatment optimization is the main goal of the system. The document refers to the technology of the system and the clinical requirements and the types of medical data needed for exploitation in the case of nephroblastoma. The outcome of an initial step towards the clinical adaptation and validation of the system is presented and discussed. Use of anonymized real data before and after chemotherapeutic treatment for the case of the SIOP 2001/GPOH nephroblastoma clinical trial constitutes the basis of the clinical adaptation and validation process. By using real medical data concerning nephroblastoma for a single patient in conjunction with plausible values for the model parameters (based on available literature) a reasonable prediction of the actual tumour volume shrinkage has been made possible. Obviously as more and more sets of medical data are exploited the reliability of the model "tuning" is expected to increase. The successful performance of the initial combined ACGT Oncosimulator platform, although usable up to now only as a test of principle, has been a particularly encouraging step towards the clinical translation of the system, being the first of its kind worldwide.